An oral, small molecule calcitonin gene-related peptide receptor antagonist for acute migraine treatment.
Calcitonin gene-related peptide is a neurotransmitter expressed in peripheral sensory trigeminal neurons that innervates the pain sensitive dura and meningeal blood vessels.
During a migraine attacks the transmitter is released and facilitates transmission of pain in the trigeminal vascular system.
In a randomized trial patients who received ubrogepant had a high percentage of freedom from pain and absence of bothersome symptoms at two hours after the dose, compared with placebo (Dodick D).
It is suggested that taking the drug during the premonitory phase may resolve pre-headache symptoms.
Side effects: nausea, somulence and dry mouth.
Views: 4